Bicara Therapeutics

An exciting moment for our team today as we celebrated becoming a public company by ringing the #OpeningBell at Nasdaq! This moment marks an important new chapter in our journey, reinforcing our commitment to developing therapies that could make a meaningful difference in the lives of those living with #cancer. We extend our gratitude to our hard working, dedicated and talented team whose drive and passion made this achievement possible. 🎉 #IPO

Head and neck squamous cell carcinoma (#HNSCC) remains one of the leading causes of cancer-related death and disability across the globe, and with incidence rates on the rise, it’s projected to increase by 30% by 2030. This past Sunday was #WorldHeadAndNeckCancerDay, which serves as a reminder of our shared responsibility to support those affected, reflect on the progress we’ve made, and fuel the innovation still needed to drive better, longer-lasting outcomes. At Bicara, this day reinforces why the work ahead matters, and it strengthens our commitment to advancing science that can truly change the lives of people living with HNSCC.

#DYK 1 in 3 children in Massachusetts are at risk of clothing insecurity and may not have access to school-appropriate clothing or essential supplies? That’s why we partnered with Life Science Cares Boston and Cradles to Crayons Massachusetts to help local kids start the school year with confidence. Together, we helped organize back-to-school essentials for children in need, ensuring they’re ready to learn and thrive. This effort was a powerful reminder of how something as simple as a backpack or a warm jacket can break down barriers to education and play. We’re grateful to Cradles to Crayons for the opportunity to support your incredible mission, and to our amazing team for showing up with heart and hands to give back and grow together.

At Bicara, we believe strong science starts with strong people, so we’re excited to shine a spotlight on one of the leaders helping shape our culture. With 18 years of experience in HR and the past 10 in the life sciences industry, Pauline Dufresne brings a thoughtful, people-centered approach to building teams and scaling with purpose. “Bicara’s culture of high integrity, perseverance, and respect resonated with my personal values. I am also appreciative of the opportunity to work alongside exceptional leaders and to be tasked with the challenge of quickly scaling a late-stage biotech company.” She shares more about herself below.

Our CEO Claire Mazumdar joined Luke Timmerman on The Long Run podcast to discuss our progress developing a bifunctional antibody for patients with HPV-negative #headandneckcancer, a population with limited treatment options. Listen in to hear more about the science behind our approach, what sets Bicara apart, and what's ahead in potentially delivering a new treatment option for HNSCC patients. https://lnkd.in/gNYVds-x

Last week, the Bicara team came together for a virtual + in-person happy hour full of laughs, connection, and trivia. We believe the same energy and collaboration that drive our science also shape our culture. We put our team to the test with a variety of topics, and they showed off some serious brainpower. Check out some photos from it below! 

Head and neck cancers account for nearly 4% of all #cancers in the United States. When caught early, they carry an 80% survival rate, but early diagnosis is still far too uncommon.  We’re working toward a future where more patients become survivors, and it starts with education and awareness. Monthly head and neck self-exams are an opportunity to get familiar with what is normal for you. This can help you notice changes early and prompt a conversation with your doctor or dentist.

June honors #NationalCancerSurvivorsMonth, a time to recognize the strength and resilience of the more than 18 million in the U.S. who live with a history of cancer. That number is expected to grow to 26 million by 2040, highlighting the importance of continued progress in detection, care, and treatment. At Bicara, we are humbled to be part of the journey and are dedicated to bringing innovative therapies that have the potential to transform the lives of patients who are impacted by solid tumor #cancers.

We’re thrilled to share that our CEO, Claire Mazumdar, has been named a 2025 New England winner of the EY #EntrepreneurOfTheYear award!    This recognition is a testament to Claire’s bold vision and unwavering commitment to transforming treatment for patients. Her leadership shapes a culture of innovation at Bicara, where scientific advancements are a priority, and patients are always at the center. We’re also proud to celebrate Bicara board member Kate Haviland for receiving this honor. It’s a privilege to work alongside leaders who are reimagining what’s possible in medicine. Congratulations, Claire and Kate, on this well-deserved recognition! View the full list of finalists at: https://lnkd.in/eYTjrgzP

Are you or a loved one living with head and neck cancer? The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients. Bicara    https://lnkd.in/gCZnU69k   #ClinicalTrial #HeadAndNeckCancer #CancerResearch